Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer.
about
Solid, non-skin, post-liver transplant tumors: Key role of lifestyle and immunosuppression managementSafety and Efficacy Endpoints for Mesenchymal Stromal Cell Therapy in Renal Transplant RecipientsSkin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer?Burden of de novo malignancy in the liver transplant recipientA systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipientsReviewing 15 years of experience with sirolimusEffect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.Advanced treatment for basal cell carcinomas.Sirolimus Increases T-Cell Abundance in the Sun Exposed Skin of Kidney Transplant RecipientsThe cutting edge of skin cancer in transplant recipients: scientific retreat of international transplant Skin Cancer Collaborative and Skin Cancer in Organ Transplant Patients EuropeMalignant and noninvasive skin tumours in renal transplant recipientsA randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients.Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis.Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotypeCancer in the transplant recipient.Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcomeAn evaluation of sirolimus in renal transplantation.A drug safety evaluation of everolimus in kidney transplantation.Exploring new frontiers: sirolimus as a pharmacokinetic modulator in advanced cancer patients.Immunostimulatory activity of lifespan-extending agents.The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients?Genetics and nonmelanoma skin cancer in kidney transplant recipients.Immunological risks of minimization strategies.Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?Renal cancer in kidney transplanted patients.Post-transplantation malignancies: here today, gone tomorrow?Transplantation of kidneys with tumors.Safety of mTOR inhibitors in adult solid organ transplantation.Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas.Azathioprine and Risk of Skin Cancer in Organ Transplant Recipients: Systematic Review and Meta-Analysis.Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.Molecular signaling cascades involved in nonmelanoma skin carcinogenesis.Epidemiology and clinical evolution of non-melanoma skin cancer in renal transplant recipients: a single-center experience in São Paulo, Brazil.Skin Cancers in Organ Transplant Recipients.Clinical and Economic Consequences of Early Cancer After Kidney Transplantation in Contemporary Practice.Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients.Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.
P2860
Q26772295-6478C54C-BDBE-439E-8654-97DC9B954795Q26799916-3F629A94-6106-4871-80DA-4477B05E05ACQ26851436-2585CA2C-5091-4AD4-AD2B-33084443D335Q26859216-6CDC54AF-51E2-4A74-B887-A0E7319D83E3Q27000107-0DFF5A4E-B325-4CDA-ABDC-C507E87E88C2Q28080955-09ACD398-220F-472E-8C3A-0F9815DFE673Q30871643-F40595BC-0B2B-4DCE-880B-461B699BF85CQ33790684-5AECFA30-79A0-4912-AD09-9D002A88CDA9Q33873997-89F55A0D-9734-498B-992F-382F206EDF37Q34111987-FC32854B-B3E3-4887-9F27-EFEE2532C722Q34268585-2299E3FE-5375-41BA-8372-86E782795251Q34805919-AB4FE7CB-7309-4246-9A47-1AF900C5C08EQ36051817-0FE34E7A-8C7A-4804-933D-6D166EFC311CQ36610844-549B4DE9-5467-4F2F-9D04-9221340B87A2Q36938488-A5D4D86D-12B5-45B2-871D-6513D08B731CQ37088225-68474C12-78ED-4633-AB2C-B765AEADD466Q38038696-7426C69A-F775-4226-82EF-438780855743Q38041260-DE6B87AE-D901-434D-B75B-3726A1D3A7E0Q38069181-FC41DE9B-E3F5-4138-80DE-119EF625BAE9Q38175673-A195B45A-AB35-43DC-AD61-E3753BE86C25Q38195885-32354ABB-533B-446F-8CD0-07A147C8A961Q38210623-F42F6088-4E3D-447C-AE0F-8C8BC93D6233Q38223160-928D49B6-95D0-46D1-AD32-35F05E286001Q38328785-C7560615-87CB-42EC-A616-453C52A46C6BQ38330222-A36D6CB0-4465-42F8-A9E5-71FEA9BC1B50Q38391150-F024A8D0-AAC9-473E-BE4C-550CEF7F267DQ38533271-A31D18C6-49B4-4794-A19F-1604CD1D05A9Q38552310-96290544-D593-4BA7-A520-2703CD411977Q38611709-AFF6DF90-0D98-4543-AFDB-B5DD2330CE5AQ38640502-566FA04E-70D0-4EFD-AC30-72A8B013429EQ38669190-9C95499D-0858-412F-AB44-B98A1E290212Q38684394-0E4E44CF-8466-4700-9DEE-51B02ED85ED2Q38830835-DF972358-270E-4DD9-960C-89FA3DE7DDE4Q38914374-62AC94F6-671C-4B95-B721-0C0770A6396BQ38966698-09A87D45-9183-481A-9AC8-0CD7C9720FE9Q39059423-A161201D-0B5A-4A8F-845C-7BE00D1E6606Q39337780-EAE8DEEF-C377-45B9-802C-4C8288A6E34FQ39525547-89445F49-433E-4CC2-8AFD-8F2CFC437FD2Q39573385-1E7D3753-9672-41F5-9221-65C822D1035AQ39757990-2984EF25-8CE2-4571-BAF3-488502BC317C
P2860
Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Randomized controlled trial of ...... k for nonmelanoma skin cancer.
@en
Randomized controlled trial of ...... k for nonmelanoma skin cancer.
@nl
type
label
Randomized controlled trial of ...... k for nonmelanoma skin cancer.
@en
Randomized controlled trial of ...... k for nonmelanoma skin cancer.
@nl
prefLabel
Randomized controlled trial of ...... k for nonmelanoma skin cancer.
@en
Randomized controlled trial of ...... k for nonmelanoma skin cancer.
@nl
P2093
P2860
P1476
Randomized controlled trial of ...... k for nonmelanoma skin cancer.
@en
P2093
P2860
P304
P356
10.1111/J.1600-6143.2012.04004.X
P407
P577
2012-03-15T00:00:00Z